Holen Sie sich die Stockscreener-App
74.22
0.46%
-0.34
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$74.56
Offen:
$73.89
24-Stunden-Volumen:
3.49M
Relative Volume:
0.68
Marktkapitalisierung:
$230.10B
Einnahmen:
$54.07B
Nettoeinkommen (Verlust:
$7.04B
KGV:
32.91
EPS:
2.255
Netto-Cashflow:
$7.28B
1W Leistung:
+0.87%
1M Leistung:
+9.21%
6M Leistung:
-13.25%
1J Leistung:
+14.03%
1-Tages-Spanne:
$73.54
$74.50
1-Wochen-Bereich:
$73.54
$74.97
52-Wochen-Spanne:
$62.75
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Firmenname
Astrazeneca PLC
Sektor
Branche
Telefon
44 20 3749 5000
Adresse
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Vergleichen Sie AZN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
74.22 | 230.10B | 54.07B | 7.04B | 7.28B | 2.255 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca PLC Aktie (AZN) Neueste Nachrichten
3 Magnificent Growth Stocks to Buy Right Now - The Motley Fool
AstraZeneca receives A1 rating upgrade from Moody's, outlook stable By Investing.com - Investing.com Australia
AstraZeneca receives A1 rating upgrade from Moody's, outlook stable - Investing.com
Moody's Lifts AstraZeneca's Ratings, Revises Outlook to Stable -February 21, 2025 at 11:51 am EST - Marketscreener.com
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca - Business Wire
Levi & Korsinsky Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming DeadlineAZN - ACCESS Newswire
2025-02-21 | FINAL REMINDER AZN DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts AstraZeneca PLC Investors to Participate in the Class Action Lawsuit | NDAQ:AZN | Press Release - Stockhouse Publishing
Meitav Investment House Ltd. Buys 205,000 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Atria Wealth Solutions Inc. Acquires 6,970 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Bryn Mawr Capital Management LLC Has $1.03 Million Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca Target of Unusually Large Options Trading (NASDAQ:AZN) - Defense World
AZN Deadline: AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit Filed by The Rosen Law Firm - PR Newswire
AstraZeneca PLC (AZN): Among the Best Global Stocks to Buy According to Hedge Funds - Insider Monkey
Final Deadline for the AstraZeneca PLC Securities LawsuitContact the DJS Law Group to Discuss Your RightsAZN - The Malaysian Reserve
FibroGen sells China unit to AstraZeneca for $160m - Pharmaceutical Technology
AstraZeneca Stock: Strategic Expansion in Chinese Market Intensifies - sharewise
Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million - Benzinga India
US CDC vaccine advisory meeting to be postponed, Stat News reports -February 20, 2025 at 01:06 pm EST - Marketscreener.com
JPMorgan Chase & Co. Reaffirms Overweight Rating for AstraZeneca (LON:AZN) - MarketBeat
AstraZeneca deepens China presence with FibroGen deal - BioPharma Dive
Faruqi & Faruqi Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025AZN - Morningstar
AstraZeneca PLC Class Action: The Gross Law Firm Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025AZN - Finansavisen
Here’s Why AstraZeneca PLC (AZN) Traded Lower in Q4 - Insider Monkey
2025-02-20 | Shareholders that lost money on AstraZeneca PLC(AZN) Urged to Join Class ActionContact Levi & Korsinsky to Learn More | NDAQ:AZN | Press Release - Stockhouse Publishing
AstraZeneca to buy FibroGen's China unit for $160 million -February 20, 2025 at 07:04 am EST - Marketscreener.com
FibroGen sells China unit to AstraZeneca for $160 million (FGEN:NASDAQ) - Seeking Alpha
FibroGen sells China unit to AstraZeneca in deal worth $160 million -February 20, 2025 at 06:40 am EST - Marketscreener.com
Catalyst Capital Advisors LLC Has $29,000 Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca (LON:AZN) Given “Overweight” Rating at JPMorgan Chase & Co. - Defense World
2025-02-19 | Shareholders that Lost Money on AstraZeneca PLC (AZN) Should Contact Levi & Korsinsky about Pending Class ActionAZN | NDAQ:AZN | Press Release - Stockhouse Publishing
AstraZeneca Post 2024 Earnings: Unwanted Headwinds Warrant Downgrade To Hold (AZN) - Seeking Alpha
Deadline Soon: AstraZeneca PLC (AZN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - Business Wire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca - GlobeNewswire
What's a Good Price for AstraZeneca Stock? - The Motley Fool
Ex-Dividend Reminder: Vestis Corp, ONE Gas and AstraZeneca - Nasdaq
AstraZeneca files annual report with SEC - Investing.com India
AstraZeneca PLC (NASDAQ:AZN) Short Interest Update - MarketBeat
Levi & Korsinsky Alerts AstraZeneca Investors: Lead Plaintiff Deadline for Class Action Lawsuit Approaching on February 21, 2025 - The Octant
Allspring Global Investments Holdings LLC Acquires 93,071 Shares of AstraZeneca PLC (NASDAQ:AZN) - Defense World
AstraZeneca PLC (NASDAQ:AZN) Holdings Raised by Allspring Global Investments Holdings LLC - Defense World
AstraZeneca boss takes home £15m pay packet after profits rise - Insider Media
WealthPlan Investment Management LLC Buys 4,026 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Astrazeneca 'too big to base CEO's pay on peers' -February 19, 2025 at 01:21 am EST - Marketscreener.com
PRESS DIGEST- Financial TimesFeb 19 -February 18, 2025 at 08:41 pm EST - Marketscreener.com
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca - Markets Insider
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in AstraZeneca PLC. of Class Action Lawsuit and Upcoming DeadlinesAZN - PR Newswire
AstraZeneca PLC Class Action: Levi & Korsinsky Reminds - GlobeNewswire
Investors in AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your RightsAZN - Stockhouse Publishing
AstraZeneca Hit With Us Class Action Lawsuit Over China Regulatory ProbesFT -February 18, 2025 at 01:26 pm EST - Marketscreener.com
AstraZeneca hit with US class action lawsuit over China regulatory probes - Financial Times
Astrazeneca: ‘We’re too big to base our CEO’s pay on FTSE 100 peers’ - Yahoo Finance UK
Finanzdaten der Astrazeneca PLC-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):